Developer and researcher of first-in-class drugs designed to slow the progression of neurodegenerative diseases. The company's drug consists of dual incretin receptors, enabling patients to treat Parkinson's and Alzheimer's diseases.
What you see here scratches the surface
We’ll help you find what you need
Ready to get started?
© 2020 PitchBook Data. All rights reserved. PitchBook is a financial technology company that provides data on the capital markets.